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Studies on hereditary pancreatitis have provided evidence in favor of central role for trypsin
activity in the disease. Identiﬁcation of genetic variants of trypsinogen linked the protease
to the onset of pancreatitis, and biochemical characterization proposed an enzymatic gain
of function as the initiating mechanism. Mutations of serine protease inhibitor Kazal type
1 gene (SPINK1) are shown to be associated with hereditary pancreatitis. We previously
reported that Spink3 (a mouse homolog gene of human SPINK1) deﬁcient mice showed
excessive autophagy, followed by inappropriate trypsinogen activation in the exocrine pan-
creas. These data indicate that the role of SPINK1/Spink3 is not only trypsin inhibitor,
but also negative regulator of autophagy. On the other hand, recent studies showed that
high levels of SPINK1 protein detected in a serum or urine were associated with adverse
outcome in various cancer types. It has been suggested that expression of SPINK1 and
trypsin is balanced in normal tissue, but this balance could be disrupted during tumor
progression. Based on the structural similarity between SPINK1 and epidermal growth
factor (EGF), we showed that SPINK1 protein binds and activates EGF receptor, thus act-
ing as a growth factor on tumor cell lines. In this review, we summarize the old and new
roles of SPINK1/Spink3 in trypsin inhibition, autophagy, and cancer cell growth.These new
functions of SPINK1/Spink3 may be related to the development of chronic pancreatitis.
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Chronic pancreatitis (CP) is a common disease characterized by
progressive, destructive, and inﬂammatory process of multifacto-
rial etiology that leads to irreversible obliteration of the exocrine
and endocrine pancreatic tissues and to its replacement by ﬁbrous
tissue, which ultimately results in the clinical manifestations typ-
ical of an“end-stage”disorder of pancreatic function (Steer et al.,
1995; Mergener and Baillie, 1997; Braganza et al., 2011). Further-
more, CP is a well-described risk factor for pancreatic adeno-
carcinoma (Whitcomb,2004; Lowenfels and Maisonneuve,2005),
especially in cases of hereditary pancreatitis (HP; Lowenfels et al.,
1997). In the Western countries, alcohol is generally considered
as an important risk factor for the development of CP (Gullo
et al., 1988). In addition, other metabolic, anatomical, obstruc-
tive,andautoimmuneetiologicalfactorshavealsobeenrecognized
(Steer et al.,1995; Etemad andWhitcomb,2001). Furthermore,in
recent years, several genetic risk factors for CP have been identi-
ﬁed. HP is a very rare form of early onset CP. With the exception
of the young age at diagnosis and a slower progression, the clin-
ical course, morphological features, and laboratory ﬁndings of
HP do not differ from those of patients with alcoholic CP. Gene
mutations of cationic trypsinogen (protease serine 1; PRSS1),
anionic trypsinogen (protease serine 2; PRSS2), pancreatic secre-
tory trypsin inhibitor (PSTI; serine protease inhibitor Kazal type
1; SPINK1), cystic ﬁbrosis transmembrane conductance regula-
tor (CFTR), chymotrypsinogen C (CTRC), and calcium-sensing
receptor (CASR) have been shown to be associated with HP
(Whitcomb, 2010). Although the pathogenesis of CP, including
HP, is not completely understood, the necrosis–ﬁbrosis concept
is supported by both clinical and experimental data. Necrosis–
ﬁbrosis concept is that repeated attacks of acute pancreatitis (AP)
induceCP.Animalmodelsof CPhavebeendevelopedbyinducing
repeatedepisodesofAPinthepancreasusinganadministrationof
cerulein,an analog of cholecystokinin (Neuschwander-Tetri et al.,
2000),orcholine-deﬁcientethionine-supplementeddiet(Idaetal.,
2010).
The main mechanism in the onset of AP is believed to be the
autodigestion of pancreatic structural cells by various proteases
that are activated in response to the ectopic (intrapancreatic)
activation of trypsinogen (trypsin production). A relationship
between the trypsinogen gene mutations and the onset of pan-
creatitis was initially reported in 1996 (Whitcomb et al., 1996).
The effect of mutations in SPINK1 gene on the onset of pan-
creatitis was reported in 2000 (Witt et al., 2000). Mutations
in PRSS1 gene, encoding cationic trypsinogen, play a causative
role in HP (Whitcomb et al., 1996). It has been shown that
PRSS1 mutations increase autocatalytic conversion of trypsino-
gen to active trypsin, and thus probably cause premature, intra-
pancreatic trypsinogen activation disturbing the intrapancre-
atic balance of proteases and their inhibitors (Whitcomb et al.,
1996).
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CATIONIC TRYPSINOGEN (PRSS1) AND HP
Whitcomb et al. (1996) determined the sequence of ﬁve exons of
the PRSS1 and PRSS2 genes using genomic DNA from patients
with HP. To explain why the R122H mutation might cause pan-
creatitis, Whitcomb proposed that the Arg122-Val123 autolytic
peptide bond in trypsin plays an important role in the degrada-
tion of prematurely activated trypsin in the pancreas (Whitcomb
et al., 1996). Destruction of this “failsafe mechanism” by the
R122H mutation would increase intrapancreatic trypsin activity
and disturb the protease–antiprotease equilibrium and eventually
precipitate pancreatitis. Although, in the following years, further
mutations of PRSS1 gene were discovered in patients with heredi-
taryoridiopathicCP(Teichetal.,2006),theR122H,andtheN29I
mutations are the most common PRSS1 mutations worldwide.
They have been frequently reported from Europe,NorthAmerica,
and Asia (Nishimori et al.,1999).
Several mechanisms have been proposed to explain how muta-
tions in the cationic trypsinogen gene can lead to increase of
trypsin activity. At ﬁrst, R122H mutation prevents inactivation
(autolysis) of activated trypsin (Whitcomb et al., 1996) and also
leads to an increase in the autoactivation of trypsinogen (Sahin-
Toth and Toth, 2000). N29I mutation was found to have no
effect on trypsin activity and trypsinogen stability by biochemical
analysisusingrecombinanttrypsinogen.N29Imutationishypoth-
esized to change the higher-order structure of trypsin, resulting
in decreased SPINK1 binding and increased autoactivation. As
it has been shown that changes in the sequence of the cationic
trypsinogen N-terminal peptide increased its rate of degradation,
mutations A16V,D22G,and K23R (all of which change the signal
peptide cleavage site of trypsin) may lead to increased autoactiva-
tion of trypsinogen to trypsin. 228delTCC has been hypothesized
to enhance cationic trypsinogen transcription, thereby increas-
ing activity. On the basis of these mechanisms, any of these gene
mutations can increase trypsin activity in the pancreas.
To examine the link between PRSS1 mutations and the ini-
tiation and progression of HP, Archer et al. (2006) generated a
transgenic mouse that carries a missense mutation (R122H muta-
t i o n )i nt h ePRSS1 gene. The pancreas from these transgenic mice
displayed early onset acinar cell injury and inﬂammatory cell
inﬁltration. With progressing age, the transgenic mice developed
pancreatic ﬁbrosis and display acinar cell dedifferentiation. More-
over,theexpressionof mutatedPRSS1transgeneisassociatedwith
enhanced response to cerulein-induced pancreatitis.
ANIONIC TRYPSINOGEN (PRSS2) AND HP
Although increased proteolytic activity caused by the PRSS1 gene
mutations enhances the risk for CP, it was thought that muta-
t i o n si nt h ePRSS2 gene may predispose to disease (Witt et al.,
2006). In vitro studies showed that recombinant mutated PRSS2
protein (G191R) showed a loss of trypsin activity due to a novel
tryptic cleavage site that renders the enzyme hypersensitive to
autocatalytic proteolysis. Thus, it appears that the PRSS2 variant
(G191R) mitigates intrapancreatic trypsin activity, thereby play-
ing a protective role against CP.Although the overall contribution
of G191R to disease pathogenesis is low,the functional character-
ization of G191R provides the ﬁrst example in pancreatitis for a
disease-protective genetic variant.
INTRACELLULAR TRYPSINOGEN ACTIVATION AND CP
Biological consequences of intracellular trypsinogen activation
have not been directly examined. Gaiser et al. (2011) generated
mice, which were engineered to conditionally express an endoge-
nously activated trypsinogen within pancreatic acinar cells. The
mice can express trypsin activity conditionally in the pancreatic
acinarcells.Althoughinitiationof APwasobservedwithhighlev-
els of active trypsin expression, chronic inﬂammation, or ﬁbrosis
did not develop in this mice model, suggesting that intra-acinar
activation of trypsinogen is sufﬁcient to initiateAP,but not to CP.
Because CP is sometimes observed without evidence of associ-
atednecrosis,mutatedtrypsinogenmayhaveotherfunctions,and
cause HP.
SPINK1 AND HP
SPINK1 molecule was found by two independent groups. At ﬁrst,
Kazal et al. extracted SPINK1 from bovine pancreas as a pan-
creatic secretory trypsin inhibitor (PSTI) in 1948 (Kazal et al.,
1948). The animal pancreas usually has two types of trypsin
inhibitors, basic pancreatic trypsin inhibitor (BPTI) and PSTI.
Docking site of SPINK1 and PRSS1 which is predicted by using
biological information, ZDOCK, was very similar to that of BPTI
and PRSS1 (Figure 1). However, human pancreas does not have
BPTI. The gene encoding human PSTI was named as serine pro-
tease inhibitor, Kazal type 1 (SPINK1). Mouse gene homologous
to human SPINK1 is Spink3. Hydra gene homologous to human
SPINK1 is Kazal1. The human SPINK1 gene encodes mRNA of
237bp, which is translated to a 79 amino acid peptide including
a 23 amino acid signal peptide with three intramolecular disul-
ﬁdebridges(Cys9–Cys33,Cys16–Cys35,andCys24–Cys56;Bartelt
et al., 1977; Horii et al., 1987), and the molecular weight is esti-
mated to be 6240 based on the amino acid composition. SPINK1
(PSTI) is secreted by the acinar cells of exocrine pancreas into the
pancreatic duct. It binds rapidly to trypsin and inhibits its activity
both intracellularly and extracellularly. Hence, it is an important
protective factor in the onset of pancreatitis (Hirota et al., 2006).
The liver also secretes SPINK1 protein in the systemic circulation
as one of acute phase proteins to inhibit trypsin activity in tissues
such as the pancreas. Although it is known that SPINK1 molecule
iswidelyexpressedinextrapancreatictissues,especiallyinthegas-
trointestinal and urinary tract (Marchbank et al., 1998), its roles
in these tissues are not known.
At second discovery, SPINK1 was isolated by Stenman et al.
(1982) from urine of ovarian cancer patients and was reported as
tumor-associated trypsin inhibitor (TATI). TATI was later shown
to be identical to SPINK1 (Huhtala et al.,1982). Increased expres-
sion of SPINK1 protein was reported in various cancers, such as
lung cancer (Tomita et al., 1987; Higashiyama et al., 1992), colon
cancer (Higashiyama et al., 1990; Tomita et al., 1990), liver can-
cer (Ohmachi et al., 1993), breast cancer (Ogawa et al., 1987),
prostatecancer(Tomlinsetal.,2008),andpancreascancer(Ogawa
etal.,1987;Ozakietal.,2009).Clinically,measurementof SPINK1
protein is most useful for monitoring of patients with mucinous
ovarian cancer. Increased serum concentration ofSPINK1 protein
may occur in most types of cancer (Paju and Stenman, 2006).
And,increased expression of SPINK1 protein in tumor tissues has
been reported to be associated with the poor survival in various
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FIGURE1|P R S S 1a n dtrypsin inhibitor binding.The 3-D structures of
SPINK1, BPTI, and PRSS1 were downloaded from Protein Data Bank
(accession number: SPINK1, 1cgj; BPTI, 2ptc, and PRSS1, 2ra3). Hydrogen
atoms were added to these structures by using PyMOL software. Molecular
docking simulations for PRSS1 and SPINK1 were the carried out by using
ZDOCK.
cancers. Although this appears to be explained by the coexpres-
sion of SPINK1 molecule and tumor-associated trypsin, which
is thought to participate in tumor-associated protease cascades
mediating tumor invasion (Stenman et al., 1991), but it has not
been established yet. Tomlins et al. (2008) reported that SPINK1
outlier expression is exclusively in a subset of ETS rearrangement-
negative cancer (∼10% of total cases). ETS rearrangement is that
the translocation of an ETS (E26 transformation speciﬁc) tran-
scriptionfactor(ERGorETV1)totheTMPRSS2promoterregion,
whichcontainsandrogenresponsiveelements,anditresultsinthe
aberrant androgen-regulated expression of ERG (Tomlins et al.,
2005). They found that SPINK1 outlier expression is an inde-
pendent predictor of biochemical recurrence after resection, and
observed that SPINK1 outlier expression is an independent pre-
dictor of biochemical recurrence after resection. Tonouchi et al.
(2006)reportedthatbytheDNAmicroarrayanalysisandquantita-
tive RT-PCR reaction,SPINK1 molecule is a candidate suggesting
early recurrence of intrahepatic cholangiocarcinoma after resec-
tion.TheydescribedthatthepatientswithhigherlevelsofSPINK1
mRNA expression had signiﬁcantly shorter recurrence-free sur-
vival. Gouyer et al. (2008) reported that from the conditioned
medium of HT-29 5M21 human colon cancer cells, which are
expressing a spontaneous invasive phenotype, SPINK1 molecule
was identiﬁed and characterized as the major proinvasive secreted
factor. SPINK1, which has a signal peptide, is secreted from not
only pancreatic acinar cells, but also, colon cancer cells. SPINK1
protein may work as an autocrine and/or paracrine transform-
ing factor, which is potentially involved in cancer progression,
including local invasion of the primary tumor and its metastatic
spread.
Interestingly, there are some structural similarities between
SPINK1 and epidermal growth factor (EGF); both have similar
numbers of amino acid residues (56 and 53, respectively), molec-
ular weights (about 6kD), and three intra-chain disulﬁde bridges
(Fukuoka et al., 1987; Marchbank et al., 1998). There is 50%
gene sequence homology between SPINK1 and EGF (Hunt et al.,
1974; Scheving,1983;Yamamoto et al.,1985). Ogawa et al. (1985)
reported that SPINK1 protein was mitogenic for human ﬁbrob-
lasts.SomestudiessupporttheconceptthatSPINK1proteinbinds
to the EGF receptor (EGFR). Rat monitor peptide (rat homolog
of human SPINK1) has been reported to compete with mouse
EGF for binding to EGFR of Swiss 3T3 ﬁbroblasts (Fukuoka et al.,
1987) and an EGFR-blocking antibody removed the promigra-
tory effects of SPINK1 on human HT-29 cells (Marchbank et al.,
1996).
Recently we elucidated several functions of SPINK1 molecule.
Theseincludetrypsininhibitioninvivo,autophagyregulation,and
growth stimulation.
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SPINK1 AS TRYPSIN INHIBITOR
Pancreaticdigestiveenzymesarestoredasinactivatedprecursorsin
pancreaticacinarcells.Undernormalconditions,digestiveenzyme
activation is strictly controlled to prevent autodigestion of the
pancreas,which is called pancreatitis. However,in certain circum-
stances,excessive amounts of pancreatic trypsinogen are activated
totrypsinintracellularly,resultinginactivationof otherzymogens
andautodigestionofthepancreas.SPINK1moleculeissynthesized
in acinar cells of the pancreas and is thought to inhibit the trypsin
activity in the pancreas.
Intrapancreatic balance between trypsin and SPINK1 activi-
ties is important for pancreatitis development. It is hypothesized
that mutations in SPINK1 gene that affect SPINK1 binding with
trypsin will contribute to the onset of pancreatitis. There have
been many reports of mutations in SPINK1 genes in patients with
pancreatitis, and several hypothetical roles of these mutant pro-
teins in pancreatitis (Pfutzer et al., 2000; Witt et al., 2000; Chen
et al.,2001; Kaneko et al., 2001; Kuwata et al.,2001,2003).
To analyze the importance of trypsinogen activation (trypsin
production) and its regulation by SPINK1 molecule in the onset
of pancreatitis, we generated Spink3 gene knockout mice by gene
targeting and analyzed their phenotypes (Ohmuraya et al., 2005).
The pancreatic acinar cells in knockout mouse showed excessive
autophagy (Figure 2) and enhanced tryptic activity was detected
in pancreatic acini prepared at 1day after birth (Ohmuraya et al.,
2006). All acinar cells disappeared completely after birth, indicat-
ing that Spink3 is not only a trypsin inhibitor within pancreatic
acinar cells, but also important in maintaining the integrity of
these cells.
The general mechanism to deliver cytoplasmic components to
thelysosomesiscalledautophagy(Figure3).Thebestunderstood
roleof autophagyiscellularhousekeeping,afunctionthatextends
beyond the simple removal of damaged or unwanted products
(Seglen and Bohley,1992; Kim and Klionsky,2000; Meijer,2003).
Infact,alongwithotherproteolyticsystems,lysosomeparticipates
in the continuous turnover of intracellular constituents. Not only
soluble cytosolic proteins but also organelles, such as mitochon-
dria and peroxisomes, can be removed by autophagy (Lemasters
et al.,2002; Bellu and Kiel,2003; Roberts et al.,2003). In addition
to maintaining cellular homeostasis,there is growing evidence for
FIGURE 2 |The pancreatic acinar cells of Spink3 deﬁcient mice. Many
vacuoles, autophagosomes, are appeared in Spink3 deﬁcient pancreatic
acinar cells (Right panel). N, nucleus of the acinar cell.
the participation of autophagy in processes such as cellular dif-
ferentiation, tissue remodeling, growth control, cell defense, and
adaptation to adverse environments (Hennig and Neufeld, 2002;
Jacinto and Hall,2003; Melendez et al., 2003; Otto et al.,2003).
SPINK1 AS AN AUTOPHAGY REGULATOR
The vacuoles were observed by histological examination corre-
spond to autophagosomes using autophagosome speciﬁc probe,
microtubule-associatedprotein1lightchain3(LC3-II),whichare
the hallmark of autophagy (Hashimoto et al., 2008). We reported
that conversion of trypsinogen to trypsin within the pancreatic
acinar cell was greatly suppressed in autophagy-related gene 5
(Atg5) deﬁcient acinar cells,suggesting involvement of autophagy
intrypsinogenactivationbylysosomalhydrolasesuchascathepsin
B( Figure 4; Hashimoto et al., 2008; Ohmuraya and Yamamura,
2008). In previous study,the results indicate that all known muta-
tions of SPINK1 gene are functionally innocuous for the trypsin
inhibitory activity (Kuwata et al.,2002; Kiraly et al.,2007; Ohmu-
raya et al.,2009). Hence,it is possible that HP caused by mutation
of SPINK1 gene is due to autophagy induction, but not to loss of
binding to trypsin.
Interestingly, Chera et al. (2006) reported that similar pheno-
types parallel in the endodermal epithelial cells observed upon
silencing of Kazal1 gene, which is a homolog of SPINK1 gene in
hydra.Inhydra,theendodermalepithelialcellscarryoutthediges-
tive function together with the gland cells that produce zymogens
and express the evolutionarily conserved gene Kazal1. A progres-
siveKazal1silencinginducedexcessiveautophagyinthecytoplasm
of digestivecells,anddramaticdisorganizationfollowedbyamas-
sivedeathofthesecells.ThesedatasuggeststhatSPINK1activityis
required to prevent excessive autophagy in food digestive systems.
In mammalian cells, autophagy continuously occurs at basal
level, but can be induced in response to environmental signals
including nutrients and hormones (Mizushima,2005;Mizushima
et al., 2008). The molecular machinery of autophagy is regulated
by a class I PI3K and mammalian target of rapamycin (mTOR),
which act to inhibit autophagy (Klionsky, 2005; Mizushima et al.,
2008). It is interesting to note that SPINK1 and EGF have struc-
tural similarities, including the number of amino acid residues
and the presence of three intrachain disulﬁde bridges (Scheving,
1983). Can SPINK1 bind to EGFR and stimulate its, as a growth
factor?
SPINK1 AS A GROWTH FACTOR
Spink3 deﬁcient pancreas shows no sign of regeneration of aci-
nar cells (Ohmuraya et al., 2005), and Kazal1 silencing decreases
buddingrateinhydra(Cheraetal.,2006).SPINK1proteinwaspre-
viously shown to stimulate the growth of non-neoplastic (Ogawa
et al., 1985; McKeehan et al., 1986) and neoplastic cells (Freeman
et al.,1990; Niinobu et al., 1990).
Marchbank et al. (1996) reported that SPINK1 molecule
involved in the regenerative process at the ulcer edge. The cell
migration induced by SPINK1 protein was inhibited by adding
an EGFR-blocking antibody, which suggests that SPINK1 protein
mediatedthiseffectthroughbindingtotheEGFR.Thisideaissup-
ported by a previous report that rat PSTI competed with mouse
EGF for binding to mouse Swiss 3T3 cells (Fukuoka et al., 1987),
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FIGURE3|S c heme of autophagy in mammalian cells. A portion of
cytoplasm is enclosed by isolation membrane to form an autophagosome.
Autophagosome fuses with lysosome to degrade the inside materials.The
Atg5–Atg12 conjugate localizes to the isolation membrane throughout its
elongation process. LC3 is recruited to the membrane in the Atg5-dependent
manner. Atg5–Atg12 dissociate from the membrane upon completion of
autophagosome formation, while LC3 (-II) remains on the autophagosome
membrane. Atg5 is required for elongation of the isolation membrane.
FIGURE4|S c hematic representation of autophagy within a pancreatic acinar cell in acute pancreatitis. After autophagic vacuole containing zymogen
granules fuses lysosome, the trypsinogen is activated by lysosomal hydrolases in autophagic process, and release of activated digestive enzymes inside the cell.
althoughNiinobuetal.(1990)reportedthatthebindingofhuman
125I-labeledSPINK1proteintothesamecellswasdisplacedbycold
SPINK1 protein but not EGF, suggesting a separate receptor.
Recently, we showed that SPINK1 protein binds to EGFR to
activateitsdownstreamsignaling;resultinginproliferationofpan-
creatic and breast cancer cells (Ozaki et al.,2009).We showed that
SPINK1 protein coprecipitated with EGFR in an immunoprecip-
itation experiment and that the binding afﬁnity of SPINK1 to
EGFR is about half of that of EGF using quartz-crystal microbal-
ance technique. In addition, we performed molecular docking
simulationsusingZDOCKforthefollowingpairs:EGFandEGFR;
SPINK1 and EGFR. In 2000 docking runs, each binding pairs
bound 795 and 287 times at the same position,respectively. These
data indicate that SPINK1 binds to EGFR at the same position
of EGF–EGFR binding site, but binding afﬁnity is about half
compared to EGF–EGFR afﬁnity.
Although binding afﬁnity of SPINK1–EGFR is lower than that
of EGF–EGFR,EGFR,anditsdownstreammolecules,signaltrans-
ducer and activator of transcription 3 (STAT3), v-Akt murine
thymoma viral oncogene homolog (AKT), and extracellular
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signal-regulated kinase 1/2 (ERK1/2), were phosphorylated by
SPINK1 as well as EGF. These results suggest that SPINK1 pro-
tein stimulates the proliferation of pancreatic cancer cells through
EGFR (Ozaki et al.,2009). Autophagy is regulated by PI3K–AKT–
mTORpathway(Klionsky,2005;Mizushimaetal.,2008).Secreted
SPINK1 protein may activate this pathway via EGFR to prevent
insufﬁcient or excessive autophagy, which induces cell death.
CONCLUSION
In summary, SPINK1 is a multifunctional fascinating molecule.
It is important not only in pancreatitis pathogenesis, but also in
cellular growth and death. Although generally favoring a central
rolefortrypsinactivityduringpancreatitis,noneof thehereditary
variants provides direct evidence that intracellular trypsin activ-
ity alone is sufﬁcient to initiate the CP. We proved new roles of
SPINK1molecule,namelyautophagyregulationandgrowthstim-
ulation via EGFR. These new functions of SPINK1 molecule may
be related to the development of CP. It is possible that HP caused
by mutation of the SPINK1 gene is due to autophagy induction,
but not to loss of binding to trypsin (Ohmuraya and Yamamura,
2008).Asnextsteps,humanSPINK1replacementmodelsinSpink3
knockout mice are in progress.
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